Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

BACKGROUND: Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to escalating healthcare costs. OBJECTIVES: The aim of this study was to evaluate the cost effectiveness of immune checkp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Haiying, Xin, Wenxiu, Tong, Yinghui, Sun, Jiao, Xu, Gaoqi, Ye, Ziqi, Rao, Yuefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467260/
https://www.ncbi.nlm.nih.gov/pubmed/32877435
http://dx.doi.org/10.1371/journal.pone.0238536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467260/
https://www.ncbi.nlm.nih.gov/pubmed/32877435
http://dx.doi.org/10.1371/journal.pone.0238536

Ejemplares similares